Mary W. Redman, Ph.D.
Affiliations: | 2004 | University of Washington, Seattle, Seattle, WA |
Area:
StatisticsGoogle:
"Mary Redman"Parents
Sign in to add mentor| Babette A. Brumback | grad student | 2004 | University of Washington | |
| (Estimating causal effects with observational data: The intensity -score approach to adjusting for confounding.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kozono D, Hua X, Wu MC, et al. (2024) Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer |
| Dacic S, Travis W, Redman M, et al. (2023) International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer |
| Vaidya R, Unger JM, Qian L, et al. (2023) Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). Jco Precision Oncology. 7: e2300218 |
| Reckamp KL, Redman MW, Dragnev KH, et al. (2022) Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200912 |
| Witlox WJA, Ramaekers BLT, Lacas B, et al. (2022) Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology |
| Gettinger S, Redman MW, Herbst RS. (2022) Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply. Jama Oncology |
| Jongen A, Charlier F, Baker K, et al. (2022) Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry. Advances in Radiation Oncology. 7: 100767 |
| Hirsch FR, Redman MW, Moon J, et al. (2021) EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clinical Lung Cancer |
| Leighl NB, Redman MW, Rizvi N, et al. (2021) Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal For Immunotherapy of Cancer. 9 |
| Gettinger SN, Redman MW, Bazhenova L, et al. (2021) Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. Jama Oncology |